Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Harrow, Inc. is a U.S.-based ophthalmic pharmaceutical company focused on the development, commercialization, and distribution of prescription eye care therapies. The company operates primarily in the ophthalmology and specialty pharmaceutical industries, with a business model that spans FDA-approved branded products and ophthalmology-focused compounded medications. Harrow’s revenue is primarily driven by sales of proprietary ophthalmic drugs and cash-pay compounded formulations used by eye care professionals.
The company serves ophthalmologists, optometrists, ambulatory surgery centers, and hospitals, with a strategic emphasis on underserved or niche ophthalmic indications where limited commercial alternatives exist. Harrow positions itself through vertical integration, combining pharmaceutical development, regulatory expertise, and direct-to-provider distribution. Founded in 2006 and formerly known as Imprimis Pharmaceuticals, the company rebranded as Harrow, Inc. in 2018 to reflect its broader pharmaceutical ambitions and has since evolved from a compounding-centric model toward branded ophthalmic pharmaceuticals.
Business Operations
Harrow operates through two primary business lines: ImprimisRx and Harrow Health (Branded Pharmaceuticals). ImprimisRx is a compounding pharmacy subsidiary that formulates ophthalmic medications tailored to physician specifications, generating revenue largely through direct sales to eye care providers on a cash-pay basis. The branded pharmaceuticals business focuses on FDA-approved ophthalmic drugs marketed in the United States.
The company’s branded portfolio includes VEVYE (cyclosporine ophthalmic solution) for dry eye disease and IHEEZO (lidocaine ophthalmic gel) for ocular procedures, both commercialized through Harrow-controlled entities. Operations are primarily domestic, with manufacturing, regulatory oversight, and commercialization managed internally and through third-party partners. Harrow maintains full ownership of ImprimisRx, LLC and controls the commercialization rights to its branded assets without reliance on large pharmaceutical co-promotion agreements.
Strategic Position & Investments
Harrow’s strategy centers on building a sustainable portfolio of ophthalmology-focused pharmaceuticals by acquiring, developing, and commercializing differentiated products with established or expedited regulatory pathways. A key strategic move was the acquisition of Surface Ophthalmics assets, which added VEVYE to Harrow’s branded portfolio and expanded its presence in the chronic dry eye market.
The company continues to invest in lifecycle management, label expansions, and commercialization infrastructure to support long-term growth. Harrow has historically used disciplined capital allocation, favoring targeted acquisitions and internal development over broad-based M&A. Its focus remains on ophthalmic indications with high unmet need, limited generic competition, and strong alignment with its existing physician customer base.
Geographic Footprint
Harrow is headquartered in Nashville, Tennessee, and its operations are primarily concentrated in the United States. The company’s commercial activities, regulatory filings, and distribution efforts are U.S.-focused, reflecting its emphasis on FDA-approved products and U.S. compounding pharmacy regulations.
While Harrow does not maintain significant international manufacturing or sales operations, its products may indirectly reach international markets through limited licensing or physician use. The company’s strategic influence remains concentrated in North America, with no material revenue contribution from overseas markets based on publicly available disclosures.
Leadership & Governance
Harrow is led by an executive team with experience in specialty pharmaceuticals, capital markets, and ophthalmology-focused commercialization. The leadership emphasizes disciplined growth, regulatory compliance, and building long-term value through differentiated ophthalmic assets.
Key executives include:
- Mark L. Baum – Founder, Chairman, and Chief Executive Officer
- Andrew E. Chappell – Chief Financial Officer
- Laura A. Brown – Executive Vice President and General Counsel
The company is governed by a board of directors with backgrounds in healthcare, finance, and public company governance, aligning oversight with Harrow’s strategy of targeted growth within regulated pharmaceutical markets.